Smith & Nephew (NPW1) AI Stock Analysis

0 Followers

Smith & Nephew

(BX Swiss:NPW1)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Margin ExpansionHigher trading and gross margins, reinforced by efficiency savings delivered ahead of plan, indicate improving operating discipline. If sustained, these gains can provide durable earnings support, help offset slower procedure growth, and fund continued investment in products, commercial execution, and innovation.

Negative Factors

Lower Revenue OutlookThe revenue guidance reduction signals that near-term demand and execution are weaker than previously expected, limiting top-line momentum over the next several quarters. Although profit targets were maintained, slower sales growth can constrain operating leverage and increase reliance on cost savings.

Smith & Nephew (NPW1) vs. iShares MSCI Switzerland ETF (EWL)

Market Cap: CHF 9.67B
Dividend Yield: 2.66%
Average Volume (3M): 326
Price to Earnings (P/E): 20.2
Beta (1Y): 0.51
Revenue Growth: -3.01%
EPS Growth: 20.99%
Country: Switzerland
Employees: 18,362
Sector: Healthcare
Sector Strength: 51
Industry: Medical - Devices

Smith & Nephew Business Overview & Revenue Model

Company Description

Smith & Nephew plc, along with its subsidiaries, operates globally as a developer, manufacturer, marketer, and seller of medical technology. Its orthopaedic division offers knee implants for replacement procedures and hip implants for joint reconstru...

Smith & Nephew Earnings Call Summary

Earnings Call Date:Aug 04, 2026(Q2-2026)|Next Earnings Date:Mar 01, 2027

Earnings Call SentimentNeutral

The call balanced clear operational and financial progress (strong trading profit, margin expansion, sizeable efficiency savings, product launches and robotics/innovation momentum) against a disappointing top-line start driven by U.S. Orthopaedics and Advanced Wound Bioactives reimbursement/market frictions. Management lowered revenue growth guidance for 2026 to around 4% but maintained profit, cash flow and ROIC targets by accelerating savings and offsetting tariff impacts. Execution risk remains in Orthopaedics set deployments, skin substitute reimbursement adaptation and near-term cash timing, while multiple innovation and commercial levers are positioned to drive recovery in H2 and into 2027.

Positive Updates

Strong profitability and margin expansion

Trading profit of $566 million (up $43 million), trading margin 18.3% (up 60 bps); underlying gross profit $2.2 billion with gross margin 71.1% (up 60 bps).

Negative Updates

Revenue below expectations and guidance cut

Q2 underlying revenue growth 1.6% (revenue $1.6 billion); management revised full-year underlying revenue growth to around 4% (previously higher) due to softer start to the year.

Company Guidance

Management lowered 2026 revenue guidance to around 4% underlying growth (Q2 underlying +1.6%; Q2 revenue $1.6bn; Q2 reported +2.8% including a 120bp FX tailwind) and now expects H2 growth of 5–5.5%; H1 revenue was $3.1bn (+2.3% underlying; ADS +3.1%). They reaffirmed profit and cash targets: trading profit guidance ~8% growth excluding M&A (H1 trading profit $566m; trading margin 18.3%), ~ $1.3bn trading profit including Integrity (marginally dilutive in 2026), adjusted EPS $0.477 (+11%), basic EPS +6.2%, interim dividend $0.156 (+4%). Efficiency savings were stepped up to ~$200m for 2026 (additional $50m), with ~ $133m delivered in H1 and cumulative savings of $330m (target $325–375m); gross profit H1 $2.2bn (gross margin 71.1%, +60bps). Cash metrics: H1 trading cash flow $437m, free cash flow $231m (guidance ~ $800m for 2026), cash conversion 77%, net debt ≈ $3bn (up $260m), leverage 1.8x EBITDA; $500m buyback announced ($260m completed). Other call metrics: ROIC >10%, tariffs broadly neutral net of refunds, inventory DSI reduced (group down 72 days incl. reclassification, 40 days excl.), and a skin‑substitutes trading‑profit headwind now expected toward the upper end of the previously guided $20–40m range.

Smith & Nephew Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

CH:NPW1 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GB:HIK	74Outperform	GBP 3.36B	12.19	15.05%	3.86%	2.48%	3.36%
GB:AMS	71Outperform	GBP 616.74M	166.47	1.44%	1.66%	6.05%	-60.00%
GB:CTEC	71Outperform	GBP 4.75B	53.05	8.40%	2.20%	1.94%	-43.71%
GB:SPI	64Neutral	GBP 997.88M	-526.60	-0.26%	0.61%	1.97%	-110.22%
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
GB:PRTC	50Neutral	GBP 300.10M	167.28	0.14%	―	-4.11%	-96.92%

* Healthcare Sector Average

Performance Comparison

CH:NPW1 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
CH:NPW1	Smith & Nephew (UK)	12.56	0.41	3.40%
GB:AMS	Advanced Medical Solutions	283.00	68.49	31.93%
GB:CTEC	ConvaTec Group plc	253.40	10.60	4.37%
GB:HIK	Hikma Pharmaceuticals	1644.00	120.08	7.88%
GB:PRTC	PureTech Health	126.00	0.80	0.64%
GB:SPI	Spire Healthcare	247.50	24.03	10.75%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Smith & Nephew AI Stock Analysis